. Author manuscript; available in PMC: 2017 Jul 1.

Published in final edited form as: J Psychopharmacol. 2016 Sep 27;31(1):17–30. doi: 10.1177/0269881116668590

Table 3.

Mean BOLD activation to anticipation trials, by group.

		METH−		METH+
ROI	Hemisphere	Gain	Loss	Gain	Loss
Ventral Striatum^*^†	Left	−0.04 ± 0.95	0.27 ± 1.18	−0.23 ± 1.13	−0.88 ± 1.46
Ventral Striatum^*^†	Right	0.13 ± 1.00	0.33 ± 0.98	0.14 ± 1.20	−0.39 ± 1.14
Anterior Caudate^†	Left	0.09 ± 1.02	0.19 ± 0.70	−0.42 ± 0.72	−0.89 ± 1.57
Anterior Caudate^†	Right	0.21 ± 0.86	0.04 ± 1.23	−0.14 ± 0.58	−0.58 ± 1.28
Posterior Caudate^*^†	Left	0.02 ± 0.89	0.30 ± 0.88	−0.12 ± 0.55	−0.38 ± 1.42
Posterior Caudate^*^†	Right	0.01 ± 0.71	0.27 ± 0.73	−0.08 ± 0.57	−0.53 ± 1.28

Note: BOLD activation reported as mean ± SD. METH−: healthy comparison participants; METH+: participants with a history of methamphetamine dependence. Significant statistical values are reported in main text;

Significant group x anticipation interaction;

^†

Significant main effect of group.